Sulphonyl urea derivatives as nlrp3 inflammasome modulators
AssigneeNodThera Limited
InventorsDavid HARRISON, Alan Paul WATT, Mark G. BOCK
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
Claims20
A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Iac-1):
- or a prodrug, solvate, or pharmaceutically acceptable salt thereof, wherein:
- R2 is —(CX2×2)n—R2S, wherein n is 0, 1, or 2, and each X2 is independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally substituted with one or more halo, —CN, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, or oxo;
- R2S is 4- to 8-membered heterocycloalkyl optionally substituted with one or more C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, halo, —CN, —OH, —O(C1-C6 alkyl), —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, or oxo;
- and
- each R3S is independently C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, halo, or C3-C8 heterocycloalkyl, wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl is optionally substituted with —O(C1-C6 alkyl), —N(C1-C6 alkyl)2, halo, or —CN.
A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Iabc-1):
- or a prodrug, solvate, or pharmaceutically acceptable salt thereof, wherein:
- R2S is 4- to 8-membered heterocycloalkyl optionally substituted with one or more C1-C6 alkyl, C1-C6 haloalkyl, or oxo;
- and
- each R3S is independently C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, halo, or C3-C8 heterocycloalkyl, wherein the C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl is optionally substituted with —O(C1-C6 alkyl), —N(C1-C6 alkyl)2, halo, or —CN.
A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound selected from:
- or a prodrug, solvate, or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.